Cerus Corporation (NASDAQ:CERS) will be presenting at the AABB Symposium on Implementation of Pathogen-Reduced Blood Components taking place in Bethesda, Maryland from April 27 to 28, 2015.
Cerus’ presentation will address the INTERCEPT Blood System today and its future outlook, including:
- Current FDA approved label claims for INTERCEPT, including the ability to reduce transfusion-transmitted infectious risk in apheresis platelet components, and apheresis or whole blood derived plasma components.
- Key potential blood center operational advantages, such as improved platelet availability and reduced component wastage through early platelet release with pathogen reduction.
- Plans to expand claims to include a seven-day platelet shelf-life extension, the ability to pathogen reduce whole blood derived platelets, and the development of an INTERCEPT triple set storage kit for improved platelet collection efficiency.
- INTERCEPT red cell system developments, including the successful completion of US Phase II and European Phase III trials.
Cerus’ presentation is part of AABB’s overall symposium agenda that will cover considerations on the successful implementation of pathogen reduction for blood collectors and transfusion services. The symposium is being held in light of the recent FDA approvals, as well as a New England Journal of Medicine article released last week in which US key opinion leaders argue for an FDA mandate for pathogen reduction to mitigate residual risks due to bacterial contamination, as well as established and emerging transfusion-transmitted infections.1
In addition to US status and outlook, other presenters during the AABB symposium will cover the extensive European experience with pathogen reduction, including the implementation of INTERCEPT in Switzerland, which involved the installation and validation of the system in 13 blood transfusion centers within 11 months. (Original Source)
Shares of Cerus closed last Friday at $4.79 . CERS has a 1-year high of $7.03 and a 1-year low of $3.48. The stock’s 50-day moving average is $4.14 and its 200-day moving average is $4.77.
On the ratings front, Cerus has been the subject of a number of recent research reports. In a report issued on April 24, BTIG analyst Karen Koski initiated coverage with a Buy rating on CERS and a price target of $8, which implies an upside of 67.0% from current levels. Separately, on February 27, Cantor Fitzgerald’s Caroline Corner maintained a Buy rating on the stock and has a price target of $7.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Karen Koski and Caroline Corner have a total average return of 9.3% and -20.0% respectively. Koski has a success rate of 50.0% and is ranked #2565 out of 3581 analysts, while Corner has a success rate of 45.5% and is ranked #3482.
In total, 4 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $4.79 which is 69.7% above where the stock closed last Friday.
Cerus Corp is a biomedical products company. It is engaged indeveloping andcommercializing the INTERCEPT Blood System to enhance blood safety.